The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Escobar, M
  • Castaman, G
  • Callaghan, M
  • de Moerloose, P
  • Ducore, J
  • Hermans, C
  • Journeycake, J
  • Leissinger, C
  • Luck, J
  • Mahlangu, J
  • Miesbach, W
  • Mitha, IH
  • Negrier, C
  • Quon, D
  • Recht, M
  • Schved, JF
  • Shapiro, AD
  • Sidonio, R
  • Srivastava, A
  • Stasyshyn, O
  • Vilchevska, KV
  • Wang, M
  • Young, G
  • Alexander, WA
  • Al-Sabbagh, A
  • Bonzo, D
  • Macie, C
  • Wilkinson, TA
  • Kessler, C

Grupos

Abstract

Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in haemophilia A or B patients with inhibitors (=12 years of age). We describe here the EB safety profile from the three prospective Phase 3 clinical trials performed to date.

Datos de la publicación

ISSN/ISSNe:
1351-8216, 1365-2516

HAEMOPHILIA  WILEY

Tipo:
Article
Páginas:
921-931
PubMed:
34636112
Factor de Impacto:
1,449 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 10

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • PERSEPT, SEVENFACT, eptacog beta, haemophilia, inhibitors, recombinant FVIIa, safety

Campos de Estudio

Cita

Compartir